A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Conditions
Advanced Solid Tumor · Metastatic Solid Tumor · Soft Tissue Sarcoma (STS) · Platinum-resistant Ovarian Cancer (PROC) · Hepatocellular Carcinoma (HCC) · Colorectal Cancer (CRC) · HER2 Negative Breast Cancer · Cutaneous Melanoma · Renal Cell Carcinoma (RCC)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Contact: Study coordinator (Mahesh Seetharam, MD)Mayo Clinic in Florida, Jacksonville, Florida, United States
Contact: Study coordinator (Yujie Zhao, MD, PhD)Mayo Clinic in Minnesota, Rochester, Minnesota, United States
Contact: Study coordinator (Jian Li Campian, MD, PhD)Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Contact: Study coordinator (Viswatej Avutu, MD)Cleveland Clinic, Cleveland, Ohio, United States
Contact: Study coordinator (Wen Wee Ma, MBBS)Seoul National University Hospital, Seoul, Seoul, South Korea
Contact: Study coordinator (Seock-Ah Im, MD, PhD)St. Vincent's Hospital, Suwon, suwon, South Korea
Contact: Study coordinator (Byoung Yong Shim, MD, PhD)Yonsei University Health System, Severance Hospital, Seoul, South Korea
Contact: Study coordinator (Byoung Chul Cho, MD, PhD)Yonsei University Health System, Severance Hospital, Seoul, South Korea
Contact: Study coordinator (Jung-Yun Lee, MD, PhD)Asan Medical Center, Seoul, South Korea
Contact: Study coordinator (Jae-Lyun Lee, MD, PhD)Samsung Medical Center, Seoul, South Korea
Contact: Study coordinator (Seung Tae Kim, MD, PhD)
Study leads
Nari Yun, PhD
Study Director
GI Innovation, Inc.